News coverage about ARCA biopharma (NASDAQ:ABIO) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ARCA biopharma earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.0363392621471 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

ARCA biopharma (NASDAQ ABIO) opened at 1.325 on Tuesday. ARCA biopharma has a 12-month low of $1.30 and a 12-month high of $3.12. The company’s 50 day moving average price is $2.22 and its 200-day moving average price is $2.40. The stock’s market cap is $15.57 million.

ARCA biopharma (NASDAQ:ABIO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.59) earnings per share for the quarter. On average, analysts forecast that ARCA biopharma will post ($1.75) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-arca-biopharma-abio-stock-price/1490526.html.

About ARCA biopharma

ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).

Insider Buying and Selling by Quarter for ARCA biopharma (NASDAQ:ABIO)

Receive News & Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.